Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Sven de Vos, MD PhD, Lode Swinnen, MD, Mark Kozloff, MD, Ding Wang, MD PhD, Erin Reid, MD, Loretta Nastoupil, MD, Nathan Fowler, MD, Jaclyn Cordero, Diane D'Amico, Susan Diehl, Martin Dunbar, DrPH, Ming Zhu, PhD, Shekman Wong, PhD, Sari Heitner Enschede, MD, David Chien, MD, Rod A. Humerickhouse, MD PhD, Christopher Flowers, MD

Blood (2015) 126 (23): 255.

https://doi.org/10.1182/blood.V126.23.255.255

Published: 2015

Journal Articles

The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Sven de Vos, MD PhD, Christopher R. Flowers, MD, Ding Wang, MD PhD, Lode J. Swinnen, Nathan Fowler, MD, Erin Reid, MD, Maryella Gifford, BS, Diane D'Amico, Martin Dunbar, DRPH, Ming Zhu, PhD, Jianning Yang, PhD, Sari H. Enschede, MD, Justin L. Ricker, MD PhD, David Chien, MD, Rod A. Humerickhouse, MD PhD, Mark Kozloff, MD

Blood (2014) 124 (21): 1722.

https://doi.org/10.1182/blood.V124.21.1722.1722

Published: 2014

Journal Articles

Statins and Venous Thromboembolism In Lung Cancer

Moh'd Khushman, MD, Abdel-ghanie Abu-samra, Shatha Farhan, MD, Gordon Jacobsen, Amr Hanbali, MD, Ding Wang, MD, PhD

Blood (2010) 116 (21): 5122.

https://doi.org/10.1182/blood.V116.21.5122.5122

Published: 2010

Journal Articles

Induction of Immune Responses and Improved Survival after Infusions of T Cells Armed with Anti-CD3 X Anti-Her2/ Neu Bispecific Antibody in Stage IV Breast Cancer Patients (Phase I).

Lawrence G. Lum, MD, DSC, Ritesh Rathore, MD, Don Dizon, MD, Ding Wang, MD, Zaid Al-Kadhimi, MD, Immunotherapy Team Roger Williams Hospital, Joseph P. Uberti, MD, PhD, Voravit Ratanatharathorn, MD

Blood (2007) 110 (11): 2747.

https://doi.org/10.1182/blood.V110.11.2747.2747

Published: 2007

Journal Articles

The Treatment of Complicated and High Risk Chronic Lymphocytic Leukemia (CLL) with Fludarabine, Cyclophosphamide and Rituximab (FCR).

Vijaya Donthireddy, MD, Muhammad S. Shurafa, MD, Murad Saleh, MD, Ginny Kamboj, MD, Ding Wang, MD, Nalini Janakiraman, MD

Blood (2005) 106 (11): 5038.

https://doi.org/10.1182/blood.V106.11.5038.5038

Published: 2005

NARROW

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Statins and Venous Thromboembolism In Lung Cancer

Induction of Immune Responses and Improved Survival after Infusions of T Cells Armed with Anti-CD3 X Anti-Her2/ Neu Bispecific Antibody in Stage IV Breast Cancer Patients (Phase I).

The Treatment of Complicated and High Risk Chronic Lymphocytic Leukemia (CLL) with Fludarabine, Cyclophosphamide and Rituximab (FCR).

Email alerts

ASH Publications

American Society of Hematology

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Statins and Venous Thromboembolism In Lung Cancer

Induction of Immune Responses and Improved Survival after Infusions of T Cells Armed with Anti-CD3 X Anti-Her2/ Neu Bispecific Antibody in Stage IV Breast Cancer Patients (Phase I).

The Treatment of Complicated and High Risk Chronic Lymphocytic Leukemia (CLL) with Fludarabine, Cyclophosphamide and Rituximab (FCR).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only